Minhua Chu: KRAS G12D Inhibitor GFH375 Delivers Strong Responses in NSCLC
Minhua Chu, Managing Partner at TransitionValue Partner, shared on X:
“GenFleet Therapeutics announced that the latest clinical trial data for its small-molecule KRAS G12D inhibitor, GFH375, as a monotherapy for NSCLC patients has been selected for WCLC2025 LBA and a mini-oral presentation.
The Phase 1/2 study demonstrated that GFH375 has an overall favorable safety profile in patients with KRAS G12D-mutant solid tumors, with notable efficacy and good safety/tolerability in NSCLC patients.
As of July 15 this year, the median follow-up time for 28 NSCLC patients was 4.5 months, with tumor responses observed across multiple dose groups.
Among 26 evaluable NSCLC patients, the objective response rate (ORR) was 57.7%, and the disease control rate (DCR) was 88.5%. In the 600 mg QD, the ORR was 68.8%, and the DCR was 93.8%.”
More posts featuring Minhua Chu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023